Mitral Valve Repair Combined Coronary Artery Bypass Grafting(CABG) Verus CABG Alone on Functional Ischemic Mitral Regurgitation
Primary Purpose
Coronary Artery Disease, Mitral Valve Insufficiency
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
CABG
mitral valve annuloplasty
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
- CAD that is amenable to CABG and a clinical indication for revascularization
- Moderate mitral regurgitation in the judgment of the clinical site echocardiographer, quantitative guidelines as proposed would be: jet area between 4 cmsq to 8 cmsq, jet area/left atrial area ratio between 20% to 39%
- Age ≥ 18 years
- Mitral valve annuloplasty is applicable
Exclusion Criteria:
- Organic mitral insufficiency caused by rupture of papillary muscle, rheumatic fever, degeneration or infectious endocarditis
- Jet area of mitral valve cannot be evaluated by echocardiogram
- In combination of other procedures such as surgery on tricuspid valve, aortic valve, congenital heart diseases or diseases of the thoracic arteries
- Prior surgical or percutaneous mitral valve repair
- Contraindication to cardiopulmonary bypass (CPB)
- Clinical signs of cardiogenic shock at the time of randomization
- Treatment with medication prior to the surgery
- Severe, irreversible pulmonary hypertension in the judgment of the investigator
- Evidence of cirrhosis or liver synthetic failure
- Recent history of psychiatric disease (including drug or alcohol abuse) that is likely to impair compliance with the study, in the judgment of the investigator
Sites / Locations
- Beijing Anzhen HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
CABG+mitral valve annuloplasty
CABG
Arm Description
Participants will undergo CABG and mitral valve annuloplasty.
Participants will undergo CABG only.
Outcomes
Primary Outcome Measures
Left Ventricular End Systolic Volume Index (LVESVI)
Secondary Outcome Measures
Operative death
In-hospital death
death during the time of hospitalization
Short-term complications
Postoperative perivalvular leakage or heart failure
Rehospitalization
Re-hospitalization caused by heart failure or aggravated mitral regurgitation
Full Information
NCT ID
NCT03525041
First Posted
April 29, 2018
Last Updated
May 14, 2018
Sponsor
Beijing Anzhen Hospital
Collaborators
Beijing Municipal Science & Technology Commission
1. Study Identification
Unique Protocol Identification Number
NCT03525041
Brief Title
Mitral Valve Repair Combined Coronary Artery Bypass Grafting(CABG) Verus CABG Alone on Functional Ischemic Mitral Regurgitation
Official Title
The Randomly Controlled Trial of Optimal Surgical Method for CAD Patients Combined Moderate Functional Ischemic Mitral Regurgitation
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2017 (Actual)
Primary Completion Date
December 31, 2019 (Anticipated)
Study Completion Date
June 30, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Anzhen Hospital
Collaborators
Beijing Municipal Science & Technology Commission
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Coronary artery bypass grafting(CABG) is an effective procedure in treating severe coronary artery disease(CAD). Optimal surgical method for CAD patients with functional ischemic mitral regurgitation(FIMR) is still controversial. This study will evaluate the different effectiveness of CABG plus mitral valve annuloplasty versus CABG alone on patients with moderate FIMR.
Detailed Description
CAD is a severe health problem worldwide. It is a result of plaque buildup, and eventually leads to the reduction of blood supply on myocardium. CABG is one of the procedure to improve symptoms caused by myocardial ischemia. And it is especially effective in treating severe coronary artery disease.
FIMR is one of the most common complications of CAD. After acute myocardial infarction, FIMR will occur in 17%-55% patients, and 3%-19% of them will develop into moderate or severe MR eventually. FIMR is an important prognostic factor of CAD, the in-hospital mortality rate of patients with IMR is significantly higher in several studies. In patients with mild MR, CABG alone is enough to improve myocardial ischemia; however, in people with moderate mitral regurgitation, there is still a dispute on whether mitral valve annuloplasty is beneficial at the time of CABG. The purpose of this study is to determine the optimal surgical procedure of CAD patients combined moderate FIMR.
This study will compare the effectiveness of different surgical procedure on people with moderate FIMR by enrolling people with enrolling people with CAD who require CABG procedure and have moderate mitral regurgitation. At baseline study, a questionnaire will be assigned to undergo either CABG surgery of CABG plus mitral calve annuloplasty. Blood, urine and tissue samples will be collected after the surgery. All participants will be followed up at month 1,3,6,12, participants will take part in a medication history review, a physical examination, a blood collection to evaluate the brain natriuretic peptide and an echocardiogram.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Mitral Valve Insufficiency
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
CABG+mitral valve annuloplasty
Arm Type
Active Comparator
Arm Description
Participants will undergo CABG and mitral valve annuloplasty.
Arm Title
CABG
Arm Type
Active Comparator
Arm Description
Participants will undergo CABG only.
Intervention Type
Procedure
Intervention Name(s)
CABG
Intervention Description
CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
Intervention Type
Procedure
Intervention Name(s)
mitral valve annuloplasty
Intervention Description
Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
Primary Outcome Measure Information:
Title
Left Ventricular End Systolic Volume Index (LVESVI)
Time Frame
Measured at month 12
Secondary Outcome Measure Information:
Title
Operative death
Time Frame
Measured during operation
Title
In-hospital death
Description
death during the time of hospitalization
Time Frame
1 year
Title
Short-term complications
Description
Postoperative perivalvular leakage or heart failure
Time Frame
Measured within 1 week after operation
Title
Rehospitalization
Description
Re-hospitalization caused by heart failure or aggravated mitral regurgitation
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
CAD that is amenable to CABG and a clinical indication for revascularization
Moderate mitral regurgitation in the judgment of the clinical site echocardiographer, quantitative guidelines as proposed would be: jet area between 4 cmsq to 8 cmsq, jet area/left atrial area ratio between 20% to 39%
Age ≥ 18 years
Mitral valve annuloplasty is applicable
Exclusion Criteria:
Organic mitral insufficiency caused by rupture of papillary muscle, rheumatic fever, degeneration or infectious endocarditis
Jet area of mitral valve cannot be evaluated by echocardiogram
In combination of other procedures such as surgery on tricuspid valve, aortic valve, congenital heart diseases or diseases of the thoracic arteries
Prior surgical or percutaneous mitral valve repair
Contraindication to cardiopulmonary bypass (CPB)
Clinical signs of cardiogenic shock at the time of randomization
Treatment with medication prior to the surgery
Severe, irreversible pulmonary hypertension in the judgment of the investigator
Evidence of cirrhosis or liver synthetic failure
Recent history of psychiatric disease (including drug or alcohol abuse) that is likely to impair compliance with the study, in the judgment of the investigator
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kui Zhang, MD
Phone
86-10-64456411
Email
zhangkui725@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ran Dong, MD
Organizational Affiliation
Beijing Anzhen Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Beijing Anzhen Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kui Zhang, MD
Phone
86-10-64456411
Email
zhangkui725@hotmail.com
First Name & Middle Initial & Last Name & Degree
Ran Dong, MD
First Name & Middle Initial & Last Name & Degree
Kui Zhang, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Mitral Valve Repair Combined Coronary Artery Bypass Grafting(CABG) Verus CABG Alone on Functional Ischemic Mitral Regurgitation
We'll reach out to this number within 24 hrs